UroAlert - GU Oncology Weekly

November 13, 2024

Videos

Peer-to-Peer Clinical Conversations

MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive Prostate Cancer - Phuoc Tran & Tim Showalter

Phuoc Tran

Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in oligometastatic castration-sensitive prostate cancer.

SWOG Trial On Standard vs Extended Lymphadenectomy in Muscle Invasive Bladder Cancer - Seth Lerner

Seth Lerner

Seth Lerner discusses the SWOG study on standard versus extended lymphadenectomy for muscle-invasive bladder cancer published October 2024 in the New England Journal of Medicine.

Beyond the Abstracts

Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer - Beyond the Abstract

Patient-Reported Outcomes with Olaparib plus Abiraterone Versus Placebo plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Phase 2 Trial - Beyond the Abstract

Conference Coverage

ASTRO 2024: Pembrolizumab Monotherapy Following Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer

ASTRO 2024: Prospective Evaluation of Supplemental External Beam Radiotherapy in Higher Risk Prostate Cancer Patients Implanted with Pd-103: Long-Term Results of the 44/20/0 Trials

ASTRO 2024: Strategies and Evidence for SABR in RCC

ASTRO 2024: Integrating Novel Therapeutics with Trimodal Therapy (TMT)

ASTRO 2024: SABR for Primary RCC – Is It Ready for Primetime?

Physician-Scientist Review Articles

ESMO 2024 Quick Take Insights: A Focus on ARANOTE

Effects of Pathologic Re-Review on Tumor Stage, Grade, and Risk Stratification - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Induction Avelumab Followed by Chemoimmunotherapy and Maintenance Versus Chemotherapy Alone as First-Line Therapy in Cis-Ineligible Metastatic Urothelial Carcinoma (INDUCOMAIN): A Randomized Phase II Study

Oncological outcomes of organ-sparing cystectomy versus standard radical cystectomy in male patients diagnosed with bladder cancer.

Outcomes after robot-assisted radical cystectomy with orthotopic neobladder in women.

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer.

Distant recurrence of non-muscle invasive bladder cancer 8 years after initial treatment.

A novel approach to engineering three-dimensional bladder tumor models for drug testing.

A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.

Prognostic value of neutrophil-to-lymphocyte ratio in patients with non-muscle-invasive bladder cancer with intravesical Bacillus Calmette-Guérin immunotherapy: a systematic review and meta-analysis.

The role of re-transurethral resection of bladder tumor in patients with TaHG non muscle invasive bladder cancer.

Prospective Assessment of VI-RADS with Muscle Invasion in Urinary Bladder Cancer and Its Implication on Re-Resection/Restaging TURBT Patients.

DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.

Smoking behavior and the risks of tumor recurrence and progression in patients with non-muscle-invasive bladder cancer.

Evaluating the Clinical Impact of Ureteral Frozen Section Analysis During Radical Cystectomy: A Single-Center Retrospective Study.

MTAP Protein Status Is Highly Concordant with CDKN2A Fluorescent in Situ Hybridization and Allows Stratification of the Luminal Subtype in Muscle-Invasive Bladder Cancer - Beyond the Abstract

Penile & Urethral Cancers

Human papillomavirus (HPV) and Epstein-Barr virus (EBV) in Penile Cancer in Thailand.

New masculinities in uro-oncology: A social theory that contributes to the mental health of patients with penile cancer.

Renal Cancer

Multiarm, non-randomised, single-centre feasibility study-investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): protocol.

A National Study of the Rate of Benign Pathology After Partial Nephrectomy for T1 Renal Cell Carcinoma: Should We Be Satisfied?

High RRM2 Correlates with Mitochondrial and Immune Responses in the Eosinophilic Subtype of Clear Cell Renal Cell Carcinoma.

Volumetric body composition analysis of the Cancer Genome Atlas reveals novel body composition traits and molecular markers Associated with Renal Carcinoma outcomes.

Survival improvement over time in renal cell carcinoma treated with nephrectomy: A longitudinal propensity score-matched study.

Comprehensive assessment of the association between tumor-infiltrating immune cells and the prognosis of renal cell carcinoma.

Investigation of intrafractional spinal cord and spinal canal movement during stereotactic MR-guided online adaptive radiotherapy for kidney cancer.

First and Second-line Treatments in Metastatic Renal Cell Carcinoma.

C-reactive Protein-albumin-lymphocyte Index as a Novel Biomarker for Progression in Patients Undergoing Surgery for Renal Cancer.

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.

Prostate Cancer

Preclinical Characterization of ARX517, a Site-specific Stable PSMA-Targeted Antibody Drug Conjugate for Treatment of Metastatic Castration-Resistant Prostate Cancer.

Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial.

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer

Update on PSMA-based Prostate Cancer Imaging.

Use of Placebo in Urologic Oncology Randomized Controlled Trials.

Optimizing radiomics for prostate cancer diagnosis: feature selection strategies, machine learning classifiers, and MRI sequences.

Evaluating the Role of Ultrasound in Prostate Cancer trial - phase 1: Early experience of micro-ultrasound in the United Kingdom.

Significant Effect of Carbon-Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High-Risk Prostate Cancer Patients: A Two-Center Controlled Trial Compare With X-Ray External Beam Radiation Therapy.

Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial.

Repeatability of quantitative MR fingerprinting for T1 and T2 measurements of metastatic bone in prostate cancer patients.

Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era

Prognostic role of prostate specific antigen kinetics in primary high volume metastatic hormonal sensitive prostate cancer treated with novel hormonal therapy agents.

Prostate cancer theragnostics biomarkers: An update.

Patients' anxieties and fears: a comparison between transrectal prostate biopsy and prostate MRI.

Multi-task Bayesian model combining FDG-PET/CT imaging and clinical data for interpretable high-grade prostate cancer prognosis.

A Randomized Controlled Trial of Gamification to Increase Physical Activity Among Black and Hispanic Breast and Prostate Cancer Survivors: Rationale and Design of the ALLSTAR Clinical Trial.

Advanced Imaging for Localized Prostate Cancer.

Clarity and Nucleus RadioPharma Sign Master Services Agreement and Cu-67 SAR-bisPSMA Clinical Supply Agreement

Plain language review: the safety of relugolix combination therapy for advanced prostate cancer.

Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare.

Management of de novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and the role of Radiotherapy: A Consensus by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).

Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer.

Long-Term Adverse Effects and Complications After Prostate Cancer Treatment

The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial.

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.

Value of Whole-body Magnetic Resonance Imaging Using the MET-RADS-P Criteria for Assessing the Response to Intensified Androgen Deprivation Therapy in Metastatic Hormone-naïve and Castration-resistant Prostate Cancer.

Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer.

The inhibition effect of psoralen on prostate cancer PC3 cells via down-regulation of long non-coding RNA ENST00000510619.

5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer.

PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide.

Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions - an EAU-YAU study enhancing prostate cancer detection.

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.

Cribriform Pattern Is a Predictive Factor of PSA Recurrence in Patients Receiving Radiotherapy After Prostatectomy.

Multidimensional Healthcare Access Barriers to Prostate-Specific Antigen Testing: A Nation-Wide Panel Study in the United States From 2006 to 2020.

PSMA PET Improves Characterization of Dural-Based Intracranial Lesions in Patients with Metastatic Prostate Cancer - Beyond the Abstract

Upper Tract Tumors

A review of the performance of urinary cytology with a focus on atypia, upper tract and updates on novel ancillary testing.

Ideal cystoscopic interval after nephroureterectomy in patients with upper tract urothelial carcinoma.

Imaging for upper tract urothelial carcinoma: update of the evidence and a glimpse into the future.

Testicular Cancer

Insurance remains a major source of disparity for patients with testicular cancer: call for advocacy.

Longitudinal trends in testicular volume z scores from puberty to adulthood, sperm quality, and paternity outcomes after childhood cancer.

Epithelioid trophoblastic tumor in male patients with germ cell tumor: A clinicopathologic analysis of five cases.

Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project.

Management of Small Testicular Masses: A Delphi Consensus Study.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC